Is Novo Nordisk’s Stock Decline a Buying Opportunity?

Novo Nordisk DK0062498333

The Danish pharmaceutical giant Novo Nordisk is navigating a challenging period that would have seemed improbable just two years ago. Since the start of the year, the former market darling has shed nearly half its market capitalization, with the downward trend continuing through this Friday. A significant price target reduction from Goldman Sachs, the failure of a crucial Alzheimer’s study, and growing concerns that the explosive growth narrative for weight-loss injections like Wegovy and Ozempic is fading have all contributed to the sell-off. Investors are now questioning whether the company faces a permanent re-rating or if the current slump presents a historic entry point.